mProX™ Human FCGR3B Stable Cell Line

Product Information

Target Family

Fc Receptor

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1

Target Classification

Fc Receptor Cell Lines

Target Research Area

Orphan Receptor Research

Related Diseases

Neonatal Alloimmune Neutropenia; Paroxysmal Nocturnal Hemoglobinuria

Gene ID

Human:2215

UniProt ID

Human:O75015

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

FCGR3B, also known as Fc-gamma receptor III-B, has been studied in various research areas. In the field of lung squamous cell carcinoma (LUSC), FCGR3B was identified as one of the hub-targeted mRNAs in the miRNA-mRNA regulatory network. It showed interactions with other targeted mRNAs and provided insights into the molecular pathogenesis of LUSC. In the context of gene copy number estimation, FCGR3B was used as a validation marker for the computational method GeneToCN. The method accurately predicted copy numbers for FCGR3A, but showed reduced accuracy for FCGR3B. In multiple myeloma, FCGR3B was identified as one of the protective proteins causally associated with MM risk. It was inversely associated with MM and showed potential as a therapeutic target. In head and neck squamous cell carcinoma (HNSCC), FCGR3B was identified as one of the new markers associated with the tumor microenvironment (TME). It was used in the construction of a risk model to predict the prognosis of HNSCC patients. Finally, in dermatomyositis, FCGR3B was identified as a potential drug target based on genomic variation associated with the disease. Overall, FCGR3B has been implicated in cancer prognosis, gene copy number estimation, immune response, and drug repositioning.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human FCGR3B Stable Cell Line (S01YF-1023-PY159). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Garcia (Verified Customer)

Does FCGR3B polymorphism impact rituximab efficacy in rheumatoid arthritis? Feb 19 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

FCGR3B polymorphism, along with FCGR2A and FCGR3A, may influence the efficacy of rituximab in treating rheumatoid arthritis, although the association is not significant. Feb 19 2021

chat Casey Williams (Verified Customer)

How does FCGR3B polymorphism relate to lung cancer risk? Feb 21 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

FCGR3B polymorphism, along with other immune-related genes, might be associated with the risk of lung cancer. Feb 21 2022

Published Data

Fig.1 GPI-B7 expressed on CHO cells offers T-cell costimulation.

CHO CD16B and CHO GPI-B7 cell lines were exposed to irradiation (8000r ads) and subsequently cultured with either the control mAb X63, anti-mouse B7, or anti-human B7 antibodies. Following coating with these antibodies, the cells were introduced into the experimental setup with a T cell to CHO cell ratio of 8:1, all while PMA was maintained at a concentration of 1ng/ml.

Ref: McHugh, Rebecca S., et al. "Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80)." Proceedings of the National Academy of Sciences 92.17 (1995): 8059-8063.

Pubmed: 7544014

DOI: 10.1073/pnas.92.17.8059

Research Highlights

Zhao, Lun. et al. "Construction of Prognostic Model and miRNA-mRNA Regulatory Network for Lung Squamous Cell Carcinoma." Alternative therapies in health and medicine, 2023.
The purpose of this paper was to construct a prognostic model, miRNA-mRNA regulatory network, and protein-protein interaction (PPI) network for lung squamous cell carcinoma (LUSC) using data from the cancer genome atlas (TCGA) database. The expression matrix for 19962 mRNA transcripts (502 LUSC and 51 normal control samples) and 2205 miRNA transcripts (478 LUSC and 45 normal control samples) was downloaded and sorted. A total of 389 differentially expressed miRNAs (DE-miRNAs) were identified, with 305 being upregulated and 84 down-regulated. Using Cox regression analysis, 7 prognosis-related DE-miRNAs (PDE-miRNAs) were identified, and a prognostic model consisting of three PDE-miRNAs (hsa-miR-4746-5p, hsa-miR-556-3p, and hsa-miR-489-3p) was optimized. This model accurately predicted the grouping and prognosis of LUSC patients, as confirmed by Cox regression analysis, independent prognostic analysis, and survival curves. A miRNA-mRNA regulatory network was constructed, showing the regulatory relationship between PDE-miRNAs and targeted mRNAs. Additionally, a PPI network was created, highlighting the interaction among targeted mRNAs. The results of this study provide insights into the molecular pathogenesis of LUSC and can aid in early clinical diagnosis and treatment.
Zhao, Lun. et al. "Construction of Prognostic Model and miRNA-mRNA Regulatory Network for Lung Squamous Cell Carcinoma." Alternative therapies in health and medicine, 2023.
Pubmed: 37856813 DOI: No

Pajuste, Fanny-Dhelia; Re, Maido. "GeneToCN: an alignment-free method for gene copy number estimation directly from next-generation sequencing reads." Scientific reports, 2023.
A novel computational approach called GeneToCN has been developed to analyze genomes, specifically focusing on segmental copy number variations encompassing entire genes, some of which exhibit multiallelic patterns. GeneToCN assesses gene-specific k-mer frequencies in FASTQ files, enabling precise gene copy number inference. Validation of this method involved amy1, amy2a, and amy2b genes using ddPCR data, revealing a robust correlation (R = 0.99) between GeneToCN predictions and experimental results. Additional testing on FCGR3 genes highlighted its superior performance for FCGR3A compared to other methods but decreased accuracy for FCGR3B. Furthermore, GeneToCN demonstrated consistency across different sequencing technologies, including Illumina, PacBio, and Oxford Nanopore, in predicting copy numbers for SMN, NPY4R, and LPA Kringle IV-2 domain genes. These findings align with previous research and indicate its potential applicability across diverse sequencing platforms.
Pajuste, Fanny-Dhelia; Re, Maido. "GeneToCN: an alignment-free method for gene copy number estimation directly from next-generation sequencing reads." Scientific reports, 2023.
Pubmed: 37853040 DOI: 10.1038/s41598-023-44636-z